Adjunctive  Therapy - Principles            Archive 2001

TCTMD CME Program

TCTMD 2001 - Expert Presentation Slides

Heparin, LMW Heparins, Heparinoids & Anti-Thrombins D. J. Kereiakes  
Heparin, LMWH, Heparinoids, and Anti-Thrombins J. Zidar  
Interventional Pharmacology: Appropriate Selection & Utilization G. Dangas  
Other Pharmacological Agents Used in PCI Patients m. s. freed  
Pharmacodynamic Efficacy III: ATHENS and Munich Data G. Dangas  
Principles of Atherogenesis J. H. Chesebro  
Principles of Hematology & Antithrombotic Therapy G. Dangas  
The Bivalirudin Paradox: Safer and More Effective Than UFH and GP IIb/IIIa Inhibitors? (CACHET and REPLACE-1) N. S. Kleiman  

TCT 2001 Meeting Coverage 

TCT 2001 Symposia 

Eptifibatide - How Effective and Safe is it in ACS? (PURSUIT and ESPIRIT) J. E. Tcheng  
Non-platelet Effects of Abciximab - Potential Role in Enhancing Long-Term Survival D. J. Kereiakes  
The TARGET 6 Month Results: Implications for GP IIb/IIIa Use in ACS and PCI G. W. Stone  
Tirofiban - Best Outcomes and Least Bleeding , But Upstream Use Only? (PRISM and PRISM-PLUS, RESTORE, TACTICS-TIMI18, and TARGET) M. E. BERTRAND  

AHA 2001 Meeting Coverage

SELF-PACED LEARNING

Timing PCI: balancing the equation
Recent pharmacological studies have led to uncertainty about the role of adjunctive therapies in vascular interventions. Drs Maurice Buchbinder, Marc Cohen, and Spencer King help clarify the role of pharmacotherapy and review its use in PCI (CME credit: 1 hour, category1)
http://www.theheart.org/index.cfm?doc_id=23348